CD44v6: a target for antibody-based cancer therapy

By Heider Karl-Heinz   Kuthan Hartmut   Stehle Gerd   Munzert Gerd  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 567-579

Springer Publishing Company

Access to resources Recommend Favorite

Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

By Vizoso Francisco   Fernández José   Corte María   Bongera Miguel   Gava Richard   Allende María   García-Muñiz José   García-Morán Manuel  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 11, 2004-11 ,pp. : 679-686

Springer Publishing Company

Access to resources Recommend Favorite

CD44 Isoform 6 (CD44v6) Is a Prognostic Indicator of the Response to Neoadjuvant Chemotherapy in Cervical Carcinoma

By Costa S.   Terzano P.   Bovicelli A.   Martoni A.   Angelelli B.   Santini D.   Ceccarelli C.   Lipponen P.   Erzen M.   Syrjanen S.   Syrjanen K.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 67-73

Elsevier

Access to resources Recommend Favorite

Bladder Cancer Initiating Cells (BCICs) Are Among EMA-CD44v6+ Subset: Novel Methods for Isolating Undetermined Cancer Stem (Initiating) Cells

By Yang Y. M.   Chang J. W.  

Cancer Investigation, Vol. 26, Iss. 7, 2008-08 ,pp. : 725-733

Informa Healthcare

Access to resources Recommend Favorite

CD44v6 in developing, dysplastic and malignant oral epithelia

By Rautava J.   Soukka T.   Inki P.   Leimola-Virtanen R.   Saloniemi I.   Happonen R.-P.   Heikinheimo K.  

Oral Oncology, Vol. 39, Iss. 4, 2003-06 ,pp. : 373-379

Elsevier

Access to resources Recommend Favorite